Overview

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy. The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Indivior Inc.

Collaborator:

Reckitt Benckiser LLC

Treatments:

Analgesics, Opioid
Buprenorphine